Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00039858
Status:
COMPLETED
Last Update Posted:
2007-01-11
First Post:
2002-06-13
Brief Title:
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
Sponsor:
Encysive Pharmaceuticals
Organization:
Encysive Pharmaceuticals
Study Overview
Official Title:
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis andor treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia HIT and thrombosis syndrome HITTS or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SKF105043013 | None | None | None |